CSDX (CS Diagnostics) Net Change in Cash: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CS Diagnostics Net Change in Cash?

CS Diagnostics CSDX Net Change in Cash is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

CS Diagnostics's Net Change in Cash for the three months ended in Dec. 2025 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

CS Diagnostics Net Change in Cash Historical Data

* Premium members only.

The historical data trend for CS Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CS Diagnostics Net Change in Cash Chart

CS Diagnostics Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec24 Dec25
Net Change in Cash
Get a 7-Day Free Trial -0.00 -0.00 0.00 0.01 0.01

CS Diagnostics Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CS Diagnostics Net Change in Cash Calculation

CS Diagnostics's Net Change in Cash for the fiscal year that ended in Dec. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.006+0+0+0
=0.01

CS Diagnostics's Net Change in Cash for the quarter that ended in Dec. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $0.00 Mil mean?
CS Diagnostics (CSDX) has a Net Change in Cash of $0.00 Mil as of Dec. 2025. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for CS Diagnostics and its competitors.
Is CS Diagnostics' Net Change in Cash too high?
CS Diagnostics' current Net Change in Cash is $0.00 Mil.
How does CS Diagnostics' Net Change in Cash compare to NMTC and IRIX?
CS Diagnostics' Net Change in Cash of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Medical Devices & Instruments company?
A good Net Change in Cash depends on the Medical Devices & Instruments industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for CS Diagnostics and its competitors. CS Diagnostics's current Net Change in Cash is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current Net Change in Cash of $0.00 Mil. The current Net Change in Cash is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current Net Change in Cash is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CS Diagnostics Business Description

Address 1603 Capitol Avenue, Suite 413, Cheyenne, WY, USA, 82001
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.